Expand SGMT Menu
SGMT MENU

Sagimet Biosciences - Series A (SGMT) closed at $9.08 on November 20, 2026, down 5.6% from the previous close, on volume of 1,396,069 shares (30-day average 1,130,341).

Key numbers
  • Last close: $9.08 (November 20, 2026)
  • 52-week range: $4.50 to $11.45
  • Market value: $648.0 million
  • 30-day implied volatility (IV30): 96.0%
  • Option volume: 318 contracts (268 calls, 50 puts); 30-day average 839

Data as of November 20, 2026.

SGMT Stock Summary and Trading Ideas (Sagimet Biosciences - Series A | NASDAQ:SGMT)

Charts for Today's Stock Price and Implied Volatility in Sagimet Biosciences - Series A

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for SGMT by Theoretical Edge and Win Rates

Sentiment

Largest Multi-Leg Option Trades (30 Days)

#DateStrategyLegsContracts
1 Nov 9, 2026 Calendar Put Spread 20-Nov-26 : 15-Jan-27 10 P 10,000

Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days

News

Trading Statistics

Key Ratios

Sagimet Biosciences - Series A (SGMT) Frequently Asked Questions

What does Sagimet Biosciences - Series A do?

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

What symbol and exchange does Sagimet Biosciences - Series A shares trade?

Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.

What is Sagimet Biosciences - Series A stock price doing today?

As of November 20, 2026, SGMT stock price declined to $9.08 with 1,396,069 million shares trading.

What is Sagimet Biosciences - Series A's Beta?

SGMT has a beta of 2.17, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.17 to the broad based SPY ETF.

How much is Sagimet Biosciences - Series A worth?

SGMT has a market cap of $648.02 million. This is considered a Small Cap stock.

What is the highest and lowest price Sagimet Biosciences - Series A traded in the last 3 year period?

In the last 3 years, SGMT traded as high as $20.71 and as low as $1.73.

What are the top ETFs holding Sagimet Biosciences - Series A?

The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.

Is Sagimet Biosciences - Series A (SGMT) a good investment?

SGMT has outperformed the market in the last year with a price return of +15.7% while the SPY ETF gained +5.2%. However, in the short term, SGMT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -14.2% vs -10.1% return in SPY. But in the last 2 weeks, SGMT shares have fared better than the market returning -0.4% compared to SPY -5.9%.

What are the support and resistance levels for Sagimet Biosciences - Series A (SGMT)?

SGMT support price is $9.13 and resistance is $10.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.

Market Data Delayed 15 Minutes